The Room Temp Debacle: Leaving a vialeither lyophilized or, even worse, reconstitutedout on a lab bench for hours or a weekend is a death sentence for the peptide
N Engl J Med (2020) 383(15):141324
Some of the GLP-analog drugs available in Canada include Tirzepatide, available as Mounjaro, or Semaglutide, available as Ozempic. Both are administered as a weekly injection
[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
Research into reputable suppliers, verification of independent testing, and awareness of red flags (unusually low prices, lack of transparency, marketing medical claims) is essential for anyone considering BPC 157 peptide
Contrave carries an FDA boxed warning about an increased risk of suicidal thoughts and behavior associated with its bupropion component
